Pienomial ads

The most interesting 𝗲𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗔𝗜 𝗽𝗿𝗼𝗯𝗹𝗲𝗺 is not “𝗪𝗵𝗶𝗰𝗵 𝗺𝗼𝗱𝗲𝗹 𝗶𝘀 𝗯𝗲𝘀𝘁?” It may be: how do we create a knowledge architecture that can be trusted across very different kinds of work? A 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗲𝗻𝗱𝗽𝗼𝗶𝗻𝘁, a 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻, a legal precedent and an internal operating procedure are different knowledge domains. But they share a requirement when AI is used to support consequential decisions: the answer has to remain tied to the evidence behind it. Our new Pienomial × Intel 𝘁𝗲𝗰𝗵𝗻𝗶𝗰𝗮𝗹 𝘄𝗵𝗶𝘁𝗲𝗽𝗮𝗽𝗲𝗿 describes the Knolens architecture, the 𝗜𝗻𝘁𝗲𝗹® 𝗫𝗲𝗼𝗻® optimization work and a real-world regulatory deployment and why the same architectural properties matter across 𝗹𝗶𝗳𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀, 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀, 𝗴𝗼𝘃𝗲𝗿𝗻𝗺𝗲𝗻𝘁, 𝗹𝗲𝗴𝗮𝗹/𝗰𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝗰𝗲 and 𝗲𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀. This work brings together the expertise and contributions of Omkar Patil, Aditi Nanda, Raghumanohar Adusumilli, Sanjay Aghara, Abhishek Paliwal, Manish, Sharma, and Anupama Singh. 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝘁𝗵𝗲 𝗽𝗮𝗽𝗲𝗿: https://lnkd.in/gpdYr3gq #PienomialPienomial #Intel #IntelXeon #EnterpriseAI #KnowledgeManagement #PrivateAI #RegTech

“Can the model run on a 𝗖𝗣𝗨?” is the wrong production question. The real question is whether the entire application can meet its service levels while multiple users are querying it, while large contexts are being processed, and while the system still feels responsive. In joint engineering work with Intel, we tuned the complete Knolens workflow on 𝗜𝗻𝘁𝗲𝗹® 𝗫𝗲𝗼𝗻® 𝟲 around three competing requirements: latency, throughput and concurrency. The results and the engineering trade-offs behind them are in our new 𝘁𝗲𝗰𝗵𝗻𝗶𝗰𝗮𝗹 𝘄𝗵𝗶𝘁𝗲𝗽𝗮𝗽𝗲𝗿. The engineering work behind this was shaped by contributions from Omkar Patil, Aditi Nanda, Raghumanohar Adusumilli, Sanjay Aghara, Abhishek Paliwal, Manish, Sharma, and Anupama Singh. 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝘁𝗵𝗲 𝗽𝗮𝗽𝗲𝗿: https://lnkd.in/gpdYr3gq Pienomial #Intel #IntelXeon #AIInfrastructure #EnterpriseAI #Inference #PrivateAI

The announcement is the tip. The press release is the 10% everyone reads. The other 90% is already public buried in filings, registries and publications nobody opens. CI Lens surfaces this information before it becomes a headline. #CompetitiveIntelligence #LifeSciences #PharmaStrategy #ClinicalTrials

Your competitor saw the gap. Did you? Somewhere right now, a trial protocol just got quietly amended. A publication dropped a new data cut. A regulatory filing shifted the ground beneath your category. No press release. No alert. Just a signal and someone is already reading it. CI Lens connects Trials → Publications → Regulatory → Market into one traceable view: what changed, why it matters, where it hits your strategy. The gap doesn't stay open for long. Someone always finds it first. Make sure it's you. #CompetitiveIntelligence #PharmaCI #LifeSciences #MarketAccess #HEOR #Pienomial

A strong submission can still have weak spots. And the panel knows exactly where to look. Find the objections, evidence gaps, and pressure points before they become meeting-day surprises. Don’t wait for the questions. Rehearse them. #HTA #MarketAccess #HEOR #Pharma #ValueAssessment #Pienomial

The signal changed. Has your strategy? A trial amendment. A new filing. A publication that shifts the evidence. Any one of these can change an asset's competitive meaning overnight and the window to act on it is short. CI Lens detects the shift, connects it across sources, and interprets what it means for your position before the market catches up. Speed. Traceability. Depth of impact. Explore CI Lens. #CompetitiveIntelligence #PharmaCI #LifeSciences #MarketAccess #ClinicalTrials #Pienomial